



**NAACCR Central Registry
Webinar Series**


Shannon Vann, CTR
Jim Hofferkamp, CTR





**Female Reproductive
System Cancer Surveillance
Data Collection**




Overview of Uterine Body











Wall of the Uterine Body




endometrium
myometrium
serosa




Structures of the Female Pelvis


- Perimetrium
 - ◆ Serosa of uterine body
- Parametrium
 - ◆ Connective tissue of the pelvic floor



Structures of the Female Pelvis




Round Ligament
Sacrouterine Ligament
Broad Ligament
Uterine Ligaments




Cancer Histology for Uterine Body

- Endometrium
 - ◆ Adenocarcinoma
 - ◆ Clear cell carcinoma
 - ◆ Papillary carcinoma
 - ◆ Adenosquamous carcinoma
- Myometrium
 - ◆ Sarcoma
 - Leiomyosarcoma




Collaborative Staging for Uterine Body Cancer




CS Tumor Size Uterine Body


<u>Code</u>	<u>Description</u>
000	No mass/tumor found
001-988	Exact size in millimeters
989	989 mm or larger
990	Microscopic focus
991	Described as 'less than 1 cm'
992	Described as 'less than 2 cm' or 'greater than 1 cm' or 'between 1 cm and 2 cm'




CS Tumor Size Uterine Body	
<u>Code</u>	<u>Description</u>
993	Described as 'less than 3 cm' or 'greater than 2 cm' or 'between 2 cm and 3 cm'
994	Described as 'less than 4 cm' or 'greater than 3 cm' or 'between 3 cm and 4 cm'



CS Tumor Size Uterine Body	
<u>Code</u>	<u>Description</u>
995	Described as 'less than 5 cm' or 'greater than 4 cm' or 'between 4 cm and 5 cm'
999	Unknown




FIGO Stage for Uterine Body	
<u>FIGO</u>	<u>Description</u>
0	In situ
I	Tumor confined to uterine body
II	Tumor invades cervix but does not extend beyond uterus
III	Local and regional spread as specified in IIIA and IIIB
IVA	Tumor invades bladder mucosa and/or bowel mucosa




CS Extension Uterine Body Notes

1. Extension to bowel or bladder mucosa must be proven by biopsy
2. It is unclear to which stage previous cases were coded because cancer cells in ascites or peritoneal washings was not specifically categorized in SS77




CS Extension Uterine Body


- Code 00
 - ◆ In situ; pre-invasive; non-invasive; intraepithelial
 - ◆ Cancer in situ
 - ◆ FIGO stage 0
- Code 10
 - ◆ FIGO stage I
 - ◆ Confined to uterine body



CS Extension Uterine Body



Code 11: Confined to endometrium; FIGO IA



CS Extension Uterine Body

Code 12:
Tumor
invades <
one-half of
myometrium;
inner half of
myometrium;
FIGO IB

Labels: Fundus, Ovary, Fallopian Tube, Endometrium, Myometrium, Cervical Canal, Body of Uterus, Cervix, Vagina

NAACCR

CS Extension Uterine Body

Code 13:
Tumor
invades one-
half or more of
myometrium;
outer half of
myometrium;
FIGO IC

Labels: Fundus, Ovary, Fallopian Tube, Endometrium, Myometrium, Cervical Canal, Body of Uterus, Cervix, Vagina

NAACCR


CS Extension Uterine Body

- **Code 14**
 - ◆ Invasion of myometrium, NOS
- **Code 16**
 - ◆ Tunica serosa of visceral peritoneum (perimetrium)

NAACCR


CS Extension Uterine Body

- Code 40
 - ◆ Localized, NOS
- Code 50
 - ◆ Cervix uteri, NOS
 - ◆ FIGO Stage II, NOS



CS Extension Uterine Body

Code 51:
Endocervical
gland
involvement;
FIGO IIA



Code 52:
Cervical
stromal
invasion;
FIGO IIB






Image Source: SEER Training Website


CS Extension Uterine Body




Code 60:
Extension or
metastasis
within true
pelvis; FIGO
IIIA, FIGO III,
NOS




CS Extension Uterine Body




Code 61: Cancer cells in ascites; cancer cells in peritoneal washings; FIGO IIIA




CS Extension Uterine Body




Code 62: Ureter and vulva



CS Extension Uterine Body




Code 64: Extension or metastasis to vagina; FIGO IIIB



CS Extension Uterine Body

Code 66



Rectum
Uterus
Bladder
Vagina
Urethra
Pelvic floor muscle

FIGO Stage IIIB

Code 65: Extension or metastasis to pelvic wall; clinically frozen pelvis

Code 66: Extension or metastasis to bladder wall or rectal wall

Code 67: [(65) or (66)] and [(62) or (64)]

NAACCR

CS Extension Uterine Body

- **Code 70**
 - ◆ Extension to bowel mucosa or bladder mucosa
 - ◆ FIGO IVA
 - ◆ FIGO IV, NOS
- **Code 80**
 - ◆ Further contiguous extension
- **Code 95**
 - ◆ No evidence of primary tumor
- **Code 99**
 - ◆ Unknown

NAACCR


CS Tumor Size/Ext Eval Uterine Body

<u>Code</u>	<u>Description</u>
0	Clinical only
1	Invasive techniques
2	Autopsy (known or suspected dx)
3	Pathology
5	Pre-op tx; clinical eval
6	Pre-op tx; pathologic eval
8	Autopsy; dx not suspected
9	Unknown


NAACCR

CS Lymph Nodes Uterine Body Notes


1. Code distant nodes in Mets at Dx
2. If there is a statement that “adnexa palpated” with no mention of lymph nodes, assume lymph nodes are not involved (code 00)
3. If exploratory or definitive surgery with no mention of nodes, assume nodes are negative (code 00)
4. Regional nodes include bilateral and contralateral involvement of named nodes



CS Lymph Nodes Uterine Body




- Code 00**
None
- Code 10**
1 Hypogastric (internal iliac)
Obturator
- Code 20**
2 Common iliac
3 External iliac
4 Lateral sacral
- Code 20**
5 Para-aortic
- Mets at Dx**
6 Inguinal




Source: TNM-Interactive, UICC, 1998

CS Lymph Nodes Uterine Body


- **Code 50**
 - ◆ Regional lymph nodes: FIGO Stage IIIC, NOS
- **Code 80**
 - ◆ Regional lymph nodes, NOS
- **Code 99**
 - ◆ Unknown




CS Reg Node Eval Uterine Body	
<u>Code</u>	<u>Description</u>
0	Clinical only
1	Invasive techniques
2	Autopsy (known or suspected dx)
3	Pathology
5	Pre-op tx; clinical eval
6	Pre-op tx; pathologic eval
8	Autopsy; dx not suspected
9	Unknown




Regional Nodes Positive Uterine Body	
<u>Code</u>	<u>Description</u>
00	All nodes examined negative
01-89	Exact number of nodes positive
90	90 or more nodes positive
95	Positive aspiration or core biopsy of nodes
97	Positive nodes – number unspecified
98	No nodes examined
99	Unknown




Regional Nodes Examined Uterine Body	
<u>Code</u>	<u>Description</u>
00	No nodes examined
01-89	Exact number of nodes examined
90	90 or more nodes examined
95	No regional nodes removed, but aspiration or core biopsy of regional nodes performed
96	Regional node sampling and number of nodes unknown




Regional Nodes Examined Uterine Body	
<u>Code</u>	<u>Description</u>
97	Regional node dissection and number of nodes unknown
98	Regional nodes surgically removed but number of nodes unknown and not documented as sampling or dissection; nodes examined, but number not known
99	Unknown



CS Mets at Dx Uterine Body	
<ul style="list-style-type: none"> ■ Code 00 <ul style="list-style-type: none"> ◆ None ■ Code 11 <ul style="list-style-type: none"> ◆ Distant lymph nodes <ul style="list-style-type: none"> ◆ Superficial inguinal ■ Code 12 <ul style="list-style-type: none"> ◆ Distant lymph nodes other than code 11 <ul style="list-style-type: none"> ◆ Deep inguinal, NOS ◆ Distant lymph nodes, NOS 	




CS Mets at Dx Uterine Body	
<ul style="list-style-type: none"> ■ Code 40 <ul style="list-style-type: none"> ◆ Distant metastases except distant lymph nodes ◆ Distant metastasis, NOS ◆ Carcinomatosis ◆ Stage IVB ◆ Stage IV, NOS 	




**CS Mets at Dx
Uterine Body**

- Code 50
 - ◆ (40) + any of [(11) or (12)]
- Code 99
 - ◆ Unknown




**CS Mets Eval
Uterine Body**

<u>Code</u>	<u>Description</u>
0	Clinical only
1	Invasive techniques
2	Autopsy (known or suspected dx)
3	Pathology
5	Pre-op tx; clinical eval
6	Pre-op tx; pathologic eval
8	Autopsy; dx not suspected
9	Unknown




**CS Site-Specific Factors 1-6
Uterine Body**

- Assign code 888
 - ◆ Not applicable for this site




Case Study 1: Uterine Body

PE: Post-menopausal patient with vaginal bleeding.
Abdominal ultrasound: 6 cm mass in uterine body.
Uterine biopsy: leiomyosarcoma.
TAH & BSO path: leiomyosarcoma involves 2/3 of myometrium.




**Case Study 1
Tumor Size & Extension**

- ◆ CS Tumor size 060
 - ◆ 6 cm mass of myometrium per ultrasound
- ◆ CS Extension 13
 - ◆ Involves 2/3 of myometrium per path
- ◆ CS TS/Ext Eval 3
 - ◆ Based on pathology from TAH & BSO




**Case Study 1
Lymph Nodes**

- ◆ CS Lymph Nodes 00
 - ◆ Note 3: definitive surgery, no mention of lymph nodes
- ◆ CS Reg LN Eval 1
 - ◆ Based on surgical observation, no biopsy
- ◆ Reg LN Pos 98
 - ◆ No nodes examined
- ◆ Reg LN Exam 00
 - ◆ No nodes examined




**Case Study 1
Metastasis & SSFs**

- ◆ CS Mets at Dx 00
 - ◆ Inaccessible sites rule, presumed negative
- ◆ CS Mets Eval 0
 - ◆ Based on non-invasive clinical evidence
- ◆ CS SSF1 - SSF8 888
 - ◆ Not applicable




Case Study 2: Uterine Body

PE: Abdominal pain and distention.
Vaginal spotting. All other systems normal.
Uterine body biopsy: adenocarcinoma.
Pelvic ultrasound: frozen pelvis; no lymphadenopathy.
Chest x-ray: mild pleural effusion.




**Case Study 2
Tumor Size & Extension**

- ◆ CS Tumor Size 999
 - ◆ Size not stated
- ◆ CS Extension 65
 - ◆ Frozen pelvis
- ◆ CS TS/Ext Eval 0
 - ◆ Based on info from pelvic ultrasound




**Case Study 2
Lymph Nodes**

- ◆ CS Lymph nodes 00
 - ◆ No lymphadenopathy
- ◆ CS Reg LN Eval 0
 - ◆ Based on pelvic ultrasound
- ◆ Reg LN Pos 98
 - ◆ No nodes examined
- ◆ Reg LN Exam 00
 - ◆ No nodes examined




**Case Study 2
Metastasis & SSFs**

- ◆ CS Mets at Dx 00
 - ◆ PE, all other systems normal; pleural effusion, NOS, cannot be coded as distant metastasis
- ◆ CS Mets Eval 0
 - ◆ Based on clinical information
- ◆ CS SSF1 - SSF6 888
 - ◆ Not applicable




Case Study 3: Uterine Body

Patient admitted for TAH &BSO for uterine prolapse. No vaginal bleeding.
TAH &BSO path: Adenocarcinoma confined to the columnar epithelium of the endometrium.




Case Study 3
Tumor Size & Extension

- ◆ CS Tumor Size 999
 - ◆ Size not stated
- ◆ CS Extension 00
 - ◆ Confined to columnar epithelium of endometrium is in situ
- ◆ CS TS/Ext Eval 3
 - ◆ Based on surgical resection pathology



Case Study 3
Lymph Nodes

- ◆ CS Lymph nodes 00
 - ◆ Note 3: definitive surgery, no mention of lymph nodes
- ◆ CS Reg LN Eval 1
 - ◆ Based on surgical observation, no biopsy
- ◆ Reg LN Pos 98
 - ◆ No nodes examined
- ◆ Reg LN Exam 00
 - ◆ No nodes examined



Case Study 3
Metastasis & SSFs

- ◆ CS Mets at Dx 00
 - ◆ Inaccessible sites rule, presumed negative
- ◆ CS Mets Eval 0
 - ◆ Based on non-invasive clinical evidence
- ◆ CS SSF1 - SSF6 888
 - ◆ Not applicable

